国产创新药BD“新王”诞生！股价天量巨振！港股通创新药ETF（520880）全天放量溢价

Core Insights - The Hong Kong stock market experienced a pullback on October 22, with the Hong Kong Stock Connect Innovative Drug ETF (520880) declining by 2.74% despite a significant $11.4 billion business development deal involving Innovent Biologics [1][3] - The trading volume for the ETF reached 374 million HKD, a 30% increase from the previous period, indicating strong buying interest [1] - Innovent Biologics announced a strategic partnership with Takeda Pharmaceutical worth $11.4 billion, marking a record for business development transactions in China's innovative drug sector [3] Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) opened high but closed lower, losing its 5-day moving average [1] - Major stocks within the ETF saw mixed performance, with Innovent Biologics down 1.96% despite high trading volume of 6.288 billion HKD, while other significant stocks like CSPC Pharmaceutical and BeiGene fell over 2% [1][3] Investment Trends - The ETF is designed to track the Hang Seng Hong Kong Stock Connect Innovative Drug Selective Index, which focuses exclusively on innovative drug development companies, with over 70% of its holdings in large-cap leaders [3][4] - The index has shown strong performance, with a year-to-date increase of 108.14%, outperforming other innovative drug indices [4][5] - Analysts suggest that the recent surge in business development transactions may alleviate market concerns and highlight the long-term growth potential of China's innovative drug sector [3]